Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in pediatric Hypereosinophilic Syndrome
NCT04965636Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Started Jul 2022; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT04965636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965636.